[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

APAC Radiopharmaceuticals Market Reached USD 500.8 Million in 2012, Reports MarketsandMarkets

07 Jun 2013 • by Natalie Aster

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.

The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine–131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin’s lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).

According to the report “Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017” by MarketsandMarkets, radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinson’s disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.

Report Details:

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
Published: May, 2013
Pages: 313
Price: US$ 4,650.00

Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).

The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.

More information can be found in the report “Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017” by MarketsandMarkets.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com

Analytics & News

Weekly Digest